Open Access Green as soon as Postprint is submitted to ZB.
Presentation of epstein-barr virus latency antigens to CD8+, interferon-gamma-secreting, T lymphocytes.
Eur. J. Immunol. 29, 3995-4001 (1999)
Epstein-Barr virus (EBV) infects more than 95 % of the human population and causes an asymptomatic life-long infection in the majority of EBV carriers. Cell-mediated immunity provides resistance to EBV, as demonstrated by the occurrence of EBV-induced post-transplant lymphoproliferative disease in immunosuppressed patients. Here we looked for IFN-gamma-producing T lymphocytes in the blood of healthy donors with a rapid enzyme-linked immunospot (ELISPOT) assay, comparing as antigen presenting cells monocytes and dendritic cells (DC) infected with recombinant vaccinia virus (rVV). We found a strong CD8(+) ELISPOT response to one or more of the EBNA 3A, 3B and 3C antigens in the PBMC from 14 / 18 donors. The sensitivity of the overnight ELISPOT assay was increased using DC as antigen-presenting cells, including 3 / 3 individuals who lacked ELISPOT in PBMC. In addition, DC could markedly expand EBV-specific spots after a 7-day culture. In a smaller number of donors, we documented recognition of the subdominant LMP 1, LMP 2 and EBNA 1 antigens that are expressed in a variety of EBV-associated malignancies. Therefore our data provide more evidence for the efficacy of DC in eliciting rapid responses to EBV latency antigens in circulating CD8(+) T cells.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.000
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Language
english
Publication Year
1999
HGF-reported in Year
0
ISSN (print) / ISBN
0014-2980
e-ISSN
1521-4141
Journal
European Journal of Immunology
Quellenangaben
Volume: 29,
Issue: 12,
Pages: 3995-4001
Publisher
Wiley
Publishing Place
Hoboken
Reviewing status
Peer reviewed
Institute(s)
Institute of Molecular Immunology (IMI)
PubMed ID
10602009
Erfassungsdatum
1999-12-31